...
机译:有利的放射性抗肿瘤反应在2次出发后Lenvatinib为先进的肝细胞癌患者
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
alpha‐fetoprotein; hepatocellular carcinoma; lenvatinib; modified Response Evaluation Criteria in Solid Tumors; relative dose intensity;
机译:有利的放射性抗肿瘤反应在2次出发后Lenvatinib为先进的肝细胞癌患者
机译:Lenvatinib治疗晚期肝细胞癌患者早期肿瘤标志物响应和影像响应的相关性
机译:用Lenvatinib治疗肝细胞癌患者存活的放射响应的三个标准
机译:动力学纹理生物标志物通过基线首过灌注CT预测抗血管生成治疗后晚期肝细胞癌患者的生存率
机译:肝癌的介入放射治疗-从付款人的角度进行成本分析。
机译:Lenvatinib治疗前四周的相对剂量强度是不可切除的肝细胞癌患者有利的反应和整体生存因素
机译:完全反应Lenvatinib和Pembrolizumab在晚期肝细胞癌患者中的组合:案例报告